1st Closed Scientific Expert Meeting of the Editorial Board

The Lp(a) Journey

November 14, 2024

Professor Henry Ginsberg, Co-Chair of the Lp(a) Forum, looks at progress in Lp(a) science that has led to multiple Lp(a) targeting agents in development.

The Unanswered Questions

Professor John Chapman, Co-Chair of the Lp(a) Forum, considers key questions about Lp(a) atherogenicity, including the heterogeneity of the Lp(a) proteome and lipidome.

Who’s who in the Lp(a) proteome?

Professor Sally McCormick, University of Otago, New Zealand, discusses key research that has provided important insights into the role of the Lp(a) proteome.

The proinflammatory Lp(a) lipidome 

November 19, 2024

Dr Jeffrey Kroon, Amsterdam UMC, The Netherlands, dives deeper into the atherogenicity of Lp(a) with a focus on the pro-inflammatory lipidome.

Update on lipid lowering therapies: Muvalaplin

Professor Stephen Nicholls, Monash University, Clayton, Australia, reports early phase clinical data on the oral Lp(a) lowering small molecule, muvalaplin.

Update on lipid lowering therapies: Olpasiran

November 14, 2024

Dr Michelle O’Donoghue, Brigham and Women’s Hospital, Boston, USA, presents data on the siRNA, olpasiran, from the Phase 2 OCEAN(a) DOSE study.

Update on lipid lowering therapies: Pelacarsen

Professor Steve Nissen, Cleveland Clinic, Ohio, USA, discusses Phase 2 data about the effects of the liver-targeted antisense oligonucleotide, pelacarsen, on Lp(a).

Update on lipid lowering therapies: Lepodisiran

Dr Ann Marie Navar, University of Texas Southwestern Medical Center, Dallas, USA, presents data from a Phase 1 ascending dose study of the siRNA, lepodisiran.

Update on lipid lowering therapies: Zerlasiran

Professor Steve Nissen, Cleveland Clinic, Ohio, USA, reviews progress with the siRNA, zerlasiran, in early phase Lp(a) lowering clinical trials.

Lp(a) is an extremely atherogenic lipoprotein: Relevance to primary and secondary prevention 

November 19, 2024

Dr Gissette Reyes-Soffer, Columbia University, New York, USA, sets the scene for discussions about Lp(a) atherogenicity and its relevance to primary and secondary prevention.